Incyte ($INCY) announced an update on their ongoing clinical study. Study Overview Incyte’s new Phase 3 trial, titled “A Randomized, Double-Blind, ...

Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months ...

CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. Read why CTMX stock ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

The FDA's complete response letter highlights insufficient efficacy evidence for bevacizumab-vikj in treating wet AMD, despite previous safety confirmations. NORSE EIGHT study failed its primary ...

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study We incorporated trial data for state transitions and treatment ...

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022. The FDA has ...

The idea that inhibiting tumour angiogenesis might be an effective anticancer strategy was proposed by Folkman over thirty years ago. A number of molecules involved in angiogenesis have now been ...

In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not ...